212 related articles for article (PubMed ID: 36430448)
21. Increased expression of MUC1 and sialyl Lewis antigens in different areas of clear renal cell carcinoma.
Borzym-Kluczyk M; Radziejewska I; Cechowska-Pasko M
Clin Exp Nephrol; 2015 Aug; 19(4):732-7. PubMed ID: 25091456
[TBL] [Abstract][Full Text] [Related]
22. GYS1 induces glycogen accumulation and promotes tumor progression via the NF-κB pathway in Clear Cell Renal Carcinoma.
Chen SL; Huang QS; Huang YH; Yang X; Yang MM; He YF; Cao Y; Guan XY; Yun JP
Theranostics; 2020; 10(20):9186-9199. PubMed ID: 32802186
[TBL] [Abstract][Full Text] [Related]
23. DYSF expression in clear cell renal cell carcinoma: A retrospective study of 2 independent cohorts.
Ha M; Jeong H; Roh JS; Lee B; Han ME; Oh SO; Sohn DH; Kim YH
Urol Oncol; 2019 Oct; 37(10):735-741. PubMed ID: 31377166
[TBL] [Abstract][Full Text] [Related]
24. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
25. The Role of Serine Peptidase Inhibitor Kazal Type 13 (SPINK13) as a Clinicopathological and Prognostic Biomarker in Patients with Clear Cell Renal Cell Carcinoma.
Xu WH; Shi SN; Wang J; Xu Y; Tian X; Wan FN; Cao DL; Qu YY; Zhang HL; Ye DW
Med Sci Monit; 2019 Dec; 25():9458-9470. PubMed ID: 31825950
[TBL] [Abstract][Full Text] [Related]
26. FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity.
Dong K; Chen W; Pan X; Wang H; Sun Y; Qian C; Chen W; Wang C; Yang F; Cui X
BMC Cancer; 2022 Feb; 22(1):140. PubMed ID: 35120484
[TBL] [Abstract][Full Text] [Related]
27. The lncRNA Fer1L4 is an adverse prognostic parameter in clear-cell renal-cell carcinoma.
Cox A; Tolkach Y; Kristiansen G; Ritter M; Ellinger J
Clin Transl Oncol; 2020 Sep; 22(9):1524-1531. PubMed ID: 31965534
[TBL] [Abstract][Full Text] [Related]
28. 53 years old is a reasonable cut-off value to define young and old patients in clear cell renal cell carcinoma: a study based on TCGA and SEER database.
Tang F; Lu Z; He C; Zhang H; Wu W; He Z
BMC Cancer; 2021 May; 21(1):638. PubMed ID: 34051738
[TBL] [Abstract][Full Text] [Related]
29. High expression of long non-coding RNA SPRY4-IT1 predicts poor prognosis of clear cell renal cell carcinoma.
Zhang HM; Yang FQ; Yan Y; Che JP; Zheng JH
Int J Clin Exp Pathol; 2014; 7(9):5801-9. PubMed ID: 25337221
[TBL] [Abstract][Full Text] [Related]
30. Decreased TCL6 expression is associated with poor prognosis in patients with clear cell renal cell carcinoma.
Su H; Sun T; Wang H; Shi G; Zhang H; Sun F; Ye D
Oncotarget; 2017 Jan; 8(4):5789-5799. PubMed ID: 27494890
[TBL] [Abstract][Full Text] [Related]
31. A cluster of metabolism-related genes predict prognosis and progression of clear cell renal cell carcinoma.
Liu M; Pan Q; Xiao R; Yu Y; Lu W; Wang L
Sci Rep; 2020 Jul; 10(1):12949. PubMed ID: 32737333
[TBL] [Abstract][Full Text] [Related]
32. PIWI-Interacting RNA Pathway Genes: Potential Biomarkers for Clear Cell Renal Cell Carcinoma.
Heng B; Xie X; Zeng W; Li H; Shi L; Ye W; Wu F
Dis Markers; 2022; 2022():3480377. PubMed ID: 35273654
[TBL] [Abstract][Full Text] [Related]
33. The Identification of Zinc-Finger Protein 433 as a Possible Prognostic Biomarker for Clear-Cell Renal Cell Carcinoma.
Heyliger SO; Soliman KFA; Saulsbury MD; Reams RR
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439859
[TBL] [Abstract][Full Text] [Related]
34. Identification of Prognostic Biomarkers for Clear Cell Renal Cell Carcinoma (ccRCC) by Transcriptomics.
Zhang S; Xu X; Wang Y; Zhu Y; Wang J; Wang H; Guo J
Ann Clin Lab Sci; 2021 Sep; 51(5):597-608. PubMed ID: 34686501
[TBL] [Abstract][Full Text] [Related]
35. Prognosis of clear cell renal cell carcinoma (ccRCC) based on a six-lncRNA-based risk score: an investigation based on RNA-sequencing data.
Zeng JH; Lu W; Liang L; Chen G; Lan HH; Liang XY; Zhu X
J Transl Med; 2019 Aug; 17(1):281. PubMed ID: 31443717
[TBL] [Abstract][Full Text] [Related]
36. Role of the MUC1-C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma.
Shigeta K; Hasegawa M; Kikuchi E; Yasumizu Y; Kosaka T; Mizuno R; Mikami S; Miyajima A; Kufe D; Oya M
Cancer Sci; 2020 Oct; 111(10):3639-3652. PubMed ID: 32677159
[TBL] [Abstract][Full Text] [Related]
37. Large-scale transcriptome profiles reveal robust 20-signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma.
Xu WH; Xu Y; Tian X; Anwaier A; Liu WR; Wang J; Zhu WK; Cao DL; Wang HK; Shi GH; Qu YY; Zhang HL; Ye DW
J Cell Mol Med; 2020 Aug; 24(16):9012-9027. PubMed ID: 32567187
[TBL] [Abstract][Full Text] [Related]
38. [Correlation between metabolic syndrome and prognosis of patients with clear cell renal cell carcinoma].
Zuo MN; DU YQ; Yu LP; Dai X; Xu T
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):636-643. PubMed ID: 35950385
[TBL] [Abstract][Full Text] [Related]
39. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma.
Song Z; Li Z; Han W; Zhu C; Lou N; Li X; Luo G; Peng S; Li G; Zhao Y; Guo Y
Aging (Albany NY); 2020 Nov; 13(2):1842-1858. PubMed ID: 33201837
[TBL] [Abstract][Full Text] [Related]
40. Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma.
Reustle A; Menig LS; Leuthold P; Hofmann U; Stühler V; Schmees C; Becker M; Haag M; Klumpp V; Winter S; Büttner FA; Rausch S; Hennenlotter J; Fend F; Scharpf M; Stenzl A; Bedke J; Schwab M; Schaeffeler E
Clin Transl Med; 2022 Jun; 12(6):e883. PubMed ID: 35678045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
